XTL BiopharmaceuticalsXTLB
13F holders, Q2 2024 (June 30)4holders −1
1new positions
2sold out
1famous investor
$2.42avg. 13F price*
At the end of Q2 2024, 4 institutions reported holding XTL Biopharmaceuticals Ltd. (XTLB) in their 13F filings, down 1 from Q1 2024. 1 opened new positions and 2 sold out. The largest holders were Noked Israel Ltd ($483K), Morgan Stanley ($81K) and Citadel Advisors ($37K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- XTL Biopharmaceuticals Ltd.
- CUSIP
- 98386D307
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $13K |
| Exits | 2 | $20K |
All 13F filers, Q1 2024 → Q2 2024: 7,388 shares bought and 13,274 shares sold, net −5,886 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Noked Israel Ltd | 0.13% | No change | 198,888 | $483K |
| Morgan Stanley | 0.00% | Reduce -15.4% | 33,151 | $81K |
| Citadel Advisors | 0.00% | Add +13.2% | 15,435 | $37K |
| Rhumbline Advisers | 0.00% | New | 5,584 | $13K |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals Ltd. the manager owns.